Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Docetaxel

Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles

DRUG

Pemetrexed

Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles

Trial Locations (8)

Unknown

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

"IASO General Hospital of Athnes, Dep of Medical Oncology", Athens

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

Air Forces Military Hospital, Dep of Medical Oncology, Athens

Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens

"Sotiria General Hospital, 1st Dep of Pulmonary Diseases", Athens

"Diabalkaniko Hospital of Thessaloniki", Thessaloniki

"Theagenion Anticancer Hospital of Thessaloniki", Thessaloniki

All Listed Sponsors
collaborator

University Hospital of Crete

OTHER

lead

Hellenic Oncology Research Group

OTHER